<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28761930</article-id>
<article-id pub-id-type="pmc">5515602</article-id>
<article-id pub-id-type="publisher-id">NG2016003707</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000174</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prevalence of spinocerebellar ataxia 36 in a US population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Valera</surname>
<given-names>Juliana M.</given-names>
</name>
<degrees>MS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Diaz</surname>
<given-names>Tatyana</given-names>
</name>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Petty</surname>
<given-names>Lauren E.</given-names>
</name>
<degrees>MS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quintáns</surname>
<given-names>Beatriz</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>(2)Genomic Consulting S.L.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yáñez</surname>
<given-names>Zuleima</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boerwinkle</surname>
<given-names>Eric</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Boerwinkle: ACTIVE 5 RC2 HL 102419-02 (Boerwinkle) 09/30/2009 ? 07/31/2012 1.20 calendar NIH/NHLBI $13,687,235 Building on GWAS for NHLBI-diseases: the CHARGE Consortium This project is to re-sequence selected regions identified in GWAS of major CVD traits. 5 N01HC 55016-40-0-1 (Ballantyne) 11/15/2010 ? 10/31/16 0.60 calendar NIH/NHLBI $384,834 Atherosclerosis Risk in Communities (ARIC) Study This project will carry-out analyze and publish targeted genetic and gene-environment interaction studies on coronary heart disease, congestive heart failure, endothelial function and lung function and provide expert guidance and leadership to the ARIC Steering Committee on technical, analytical and ethical issues related to large scale genomic research. 5 U01 HG 004803-04 (Heiss) 07/17/2008 ? 05/31/2013 0.36 calendar NIH/NHGRI-University of North Carolina, Chapel Hill $348,258 Genetic Epidemiology of Causal Variants Across the Life Course To accelerate the understanding of the role and population impact of putative causal genetic variants related to complex diseases. 5 RC2 HG005697 (Hixson) 09/30/2009 ? 08/31/2012 0.60 calendar NIH/NHLBI Next-Generation Medical Resequencing of Gout Disease Genes in the ARIC Cohort This project will use next-generation sequencing technology to resequence candidate genes in gout cases and controls from the ARIC cohort to identify genetic variants that influence gout and uric acid levels. 5 R01 HL 072810-09 (Boerwinkle) 06/01/2003 ? 02/28/2013 1.20 calendar NIH/NHLBI $694,917 Modeling DNA Diversity in Reverse Cholesterol Transport The goal of this Multi-Institutional Research Project grant is to identify the genes influencing HDL-C in the population-at-large. This research not only considers the individual effects of variation in each gene, but their interactions with other genes and with the environment. We also ask if these genetic variations predict CHD beyond the traditional risk factors, such as smoking and hypertension. 1 U01 HL 096917-02 (Mosley) 07/07/2010 ? 06/30/2013 0.60 calendar NIH/NHLBI/NINDS/NEI $244,613 ARIC Neurocognitive Study (ARIC NCS) ARIC NCS will identify risk factors for dementia, mild cognitive impairment, and cognitive decline in the biracial longitudinal ARIC cohort study of the natural history of atherosclerosis. 1 R01 HL 106034-02 (Xiong) 01/10/2011 ? 12/31/2014 0.60 calendar NIH/NHLBI $376,093 Statistical Methods for Finding Missing Heritability The goal of this proposal is to use genome continuum model as a general principle, data reduction, functional data analysis techniques, and systems biology tools for developing novel and powerful statistical methods for detection interaction between genes (or pathways) with both common and rare variants and environments with both discrete and continuous measurements, and carry out genome-wide gene-environment interaction. 2 U01 GM 074492-08 (Johnson) 08/03/2005 ? 07/31/2015 0.6 calendar NIH/NIGMS $337,485 Pharmacogenomic Evaluation of Antihypertensive Responses We will provide genetic analysis of all study samples for the genome spanning studies. 1 U54 HG006542-01 (Valle) 12/05/11 ? 11/30/15 0.6 calendar NIH Baylor-Johns Hopkins Center for Mendelian Genetics Collaboration with Drs. Valle and Lupski to identify genes leading to targeted Mendelian disorders. Analyzing data to establish genotype-phenotype associations which will also include formal statistical analyses of clustering of variants within a gene or gene region. 2 U54 HG003273-09 (Gibbs) 11/01/11 ? 10/31/2012 2.4 calendar NIH $235,162 The Human Genome Sequencing Center Active close collaboration on the statistical design and analysis of projects, particular population studies. Vicki Huff (Spouse): U10 CA09843-07S6 Huff (Co-PI) 09/01/2009- 08/31/2012 NIH/NCI $20,839 annual direct costs TARGET: Wilms Tumor, P. Adamson, PI 0.6 months The major goal of this project is to use genomic data to identify genes/pathways that can be therapeutically targeted in Wilms tumor patients RP100329 Huff (PI) 3/1/2010 - 2/28/2013 CPRIT (Cancer Prevention &amp; Research Institute of Texas) $186,104 annual direct costs Next Generation Genomic Sequence Identification of the 19q 1.8 months Familial Wilms Tumor Predisposition Gene The major goal of this project is to identify the 19q familial WT gene using Next-Gen DNA sequencing data. RP110324 Huff (PI) 1/1/2011 - 12/31/2014 CPRIT (Cancer Prevention &amp; Research Institute of Texas) $351,165 annual direct costs Impact of differentiation status on tumorigenesis 3.6 months The major goal of this project is to determine whether targeting gene alterations to different cellular compartments in the developing kidney will result in Wilms tumors that exhibit distinctive molecular and clinical characteristics. CA98543 09 Huff (Chair, COG Renal Tumor Biol Comm) 3/1/2012 - 2/28/2013 NIH/NCI Children's Oncology Group (COG). P. Adamson, PI $5,017 annual direct costs 0.3 months The goal of this project is to develop more efficacious therapies for Wilms tumor patients. My role is to head up the Renal Tumor Biology Committee that oversees and guides research projects that provide biological data to further this goal. CA016672 DePinho (PI) 9/14/1998 - 6/30/2013 NIH/NCI Huff, Director $283,568 annual direct costs Cancer Center Support Grant-Sequence &amp; Microarray Facility 1.2 months The goal of this project is to provide MDACC investigators with state-of-the-art technology for DNA and RNA analyses. CA054498 Huff, PI, Subcontract 9/1/2012 - 8/31/2017 NIH/NCI Breslow (PI) $14,882 annual direct costs Late Effects of Treatment in Wilms Tumor Survivors 0.3 months The goal of this project is to assess the long- term consequences of treatment in survivors of WIlms tumor, with special reference to the role of germline WT1 mutations.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muzny</surname>
<given-names>Donna</given-names>
</name>
<degrees>MS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>1. NIH/NHGRI, 1UM1HG008898, senior investigator, 01/14/16 ? 10/31/19 2.NIH/NHLBI, 2 R01 HL078888-05A1, senior investigator, 02/15/12 ? 01/31/18 3.NHLBI-CSB-HV-2015-134-JS, HHSN268201500015C , senior investigator,09/25/15 ? 09/24/17 4.Centralized Omics REsources (CORE), HHSN68000331_NHLBI-CSB-HV- 2016-36-JS, senior investigator,09/25/16 ? 09/24/21 5.NIH DNA Sequencing Support for the eMERGE Network,1U01HG008664, senior investigator, 09/01/15 ? 05/31/19 6. NIH, U01HG007942, senior investigator, 09/22/14 ? 08/31/18</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Simons Foundation</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akhmedov</surname>
<given-names>Dmitry</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>The American Heart Association, Postdoctoral fellowship 15POST25090134</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Berdeaux</surname>
<given-names>Rebecca</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH: both attributed on the manuscript NIAMS R01AR059847 (PI) 2011-2017 NIDDK R01DK092590 (PI) 2011-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sobrido</surname>
<given-names>Maria J.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>Speaker honoraria from Actelion Pharmaceuticals, commercial entity</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Editorial Board member of: Human Mutation, Applied and Translational genomics</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other activities:</title>
<list-item>
<p>CEO of Genomic Consulting, commercial company providing clinical genetic and genomic studies, and genetic counseling.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical procedures or imaging studies:</title>
<list-item>
<p>Private clinical neurology practice and genetic diagnosis of ataxias.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Research support from Actelion Pharmaceuticlas, commercial entity. Not related to this study.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Instituto de Salud carlos III (Spain), grant number PI12/00742</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Asociaci?n Galega de Ataxias (AGA).</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gibbs</surname>
<given-names>Richard</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>Fusion Conference, NFP</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Genome Research Associates Editors</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH/NHGRI - 1UM1HG008898 (PI); U54 HG003273 (PI); R25 HG006674 (PI); 1U01HG008664 (PI); U01HG006485 PJ2 (co investigator); 2 UM1 HG006542 (co-investigator); R01HL078888 (co-investigator); U01HG007942 (co- investigator) NHLBI - HHSN268201500015C (PI); HHSN68201600033I (PI)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lupski</surname>
<given-names>James R.</given-names>
</name>
<degrees>MD, PhD, DSc</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Lasergen Inc. Regeneron Pharmaceuticals BioPontis Alliance for Rare Disorders</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>Co-Inventor on Diagnostic</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>Genomic Disorders - The Genomic Basis of Disease. J.R. Lupski and P. Stankiewicz (Eds.) Humana Press, Totowa, N.J. 2006. pp. 1-427</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Baylor College of Medicine, Professor</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Regeneron Pharmaceuticals</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH/NINDS, R01 NS058529 NIH/NHGRI, UM1 HG006542 NIH/NIGMS, R01 GM 106373</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>Lasergen Inc. 23andMe</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Geschwind</surname>
<given-names>Daniel H.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Ovid Therapeutics Inc</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>No speaker bureau</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Cell Editorial board 2014-present Molecular Autism Editorial Board 2013-present Molecular Neuropsychiatry Editorial Board 2014-present Nature Reviewer 2004-present Nature Genetics Reviewer 2002-present Nature Neuroscience Reviewer 2008-present Neurology Reviewer 2003-present Neuron Reviewer 2001-present New England Journal of Medicine Reviewer 2008-present Public Library of Science (PLoS), Genetics Reviewer 2011- present Science Reviewer and Editorial Board 2010-present Translational Psychiatry Editorial Board 2014-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>Peripheral Gene Expression Biomarkers for Autism. Filed May 25, 2005. Genetic Risk Factor for Neurodegenerative Disease. Filed June 30, 2005. Compositions and Methods for Diagnosing and Treating Brain Cancer and Identifying Neural Stem Cells. Filed September 30, 2005. Genetic Variants Underlying Human Cognition: Novel Diagnostic and Therapeutic Targets. Filed November 14, 2008. Peripheral Gene Expression Biomarkers for Autism. Filed May 15, 2009. Brain Gene Expression Changes Associated with Autism Spectrum Disorders. Filed with UCLA Intellectual Property, 2009. Full Biomarkers in Friedreich's Ataxia (provisional patent application). Filed with UCLA Intellectual Property, 2010. Signaling Networks Causing Neurodevelopmental Disorders In Human Neurons. Filed with UCLA Intellectual Property, May 3, 2011. Genes Dysregulated in Autism, Potential Biomarkers and Therapeutic Pathways. Filed with UCLA Intellectual Property, May 19, 2011. Peripheral Gene Expression Biomarkers for Autism. Filed with UCLA Intellectual Property. November 28, 2011. mTor, A Genetic Target for Treatment of Individuals with Neurocognitive Spectrum Disorders. Filed with UCLA Intellectual Property, May 11, 2012. Neuronal Regeneration. Filed with UCLA Intellectual Property, August 15, 2012. Frataxin Knock-Down Mouse. Filed with UCLA Intellectual Property, July 7, 2014. Jakmip1 Knockout Mouse. Filed with UCLA Intellectual Property, June 14, 2016. Cyfip1 Transgenic Mouse. Filed with UCLA Intellectual Property, June 14, 2016.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>Autism Spectrum Disorders Oxford University Press 2011</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>OVID Therapeutics Ltd</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>(1) Takeda Pharmaceutical Company</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) NIH/NIMH 9R01 MH100027-06 (Geschwind, PI), 03/25/13- 02/28/18 (2) NIH/NICHD 5P50 HD055784-06 (Geschwind co- Investigator) 09/04/12-05/31/17 (3) NIH/NIMH 5R37 MH060233-11 (Geschwind, PI) 07/10/99- 06/30/15 (4) NIH/NIMH 1R01 MH094714-02 (Geschwind, PI) 09/01/11- 08/31/15 (5) CIRM TR2-01814 (Geschwind co-Investigator, subaward from UCSD) 04/01/11-03/31/14 (6) NIH/NIMH 1R01 MH100028-01 (Geschwind PI of subaward from Yale) 08/01/12-07/31/17 (7) NIH/NINDS 1R01 NS073871-01A1 (Geschwind co- Investigator) 12/01/11-11/30/16 (8) NIH/NIA 5P01 AG019724-08 (Geschwind PI of subaward from UCSF) 09/01/12-8/31/17</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) The Simons Foundation (2) Adelson Medical Research Foundation (3) The Tau consortium</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>Ovid Therapeutics</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License fee payments, Technology or Inventions:</title>
<list-item>
<p>Mouse model of Freidriech Ataxia, licensed by UCLA.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perlman</surname>
<given-names>Susan</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>I have been PI on clinical drug trials for the following commercial entities and received compensation only in the form of support for the drug trial activities as specified in the contracts with the University of California, Los Angeles: 1. Erydel for ataxia telangiectasia 2. Reata for Friedreichs ataxia 3. Viropharma/Shire for Friedreichs ataxia 4. Retrotope for Friedreichs ataxia. 5. Edison for Friedreichs ataxia. 6. Teva for Huntington's disease. 7. Pfizer for Huntington's disease. 8. Biohaven for Spinocerebellar ataxia.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>National Ataxia Foundation for maintenance of the web- based database being used in a different study.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Below</surname>
<given-names>Jennifer E.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Sanofi Innovation Awards Program Whole exome sequencing of Hispanics with extreme (high and low) triglycerides: search for therapeutic targets Role: Co-I 2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>U24 OD011109 Tulane National Primate Research Center U24 AIDS SPF Breeding Colony Role: PI on subcontract 2017 1R03DC015329-01 NIH/Wayne State University Genetic Study of Stuttering Role: PI on subcontract 2016-2019 2UM1-HG006542-05 NIH/Johns Hopkins University Baylor-Johns Hopkins Center for Mendelian Genetics Role: Co-Investigator 1U01AG049506-02 Sequence-based Discovery of AD Risk &amp; Protective Alleles Alzheimer's disease is a common disease of aging characterized by loss of memory, and Alzheimer's disease clusters in families. This Project seeks to identify genes associated with increased risk of alzheimer's disease or protection from it. This newly discovered genetic information may help to identify novel treatments for this debilitating condition. Role: Co-Investigator 3U01-DK105554-02 NIH/ Broad Institute of MIT Proposal for the AMP T2D-Genes Data Coordinating Center and Web Portal Role: PI on subcontract 2016-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fogel</surname>
<given-names>Brent L.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>1. American Academy of Neurology, Speaker Honoraria 2. American Physician Institute for Advanced Professional Studies, Travel and Speaker Honoraria 3. National Ataxia Foundation, Travel</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>National Institutes of Health NIH/NINDS 5 R01 NS082094 (PI Fogel) 04/2013 - 03/2018 NIH/NIMH 5 K08 MH086297 (PI Fogel) 07/2009-04/2014</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>National Ataxia Foundation (PI Fogel) 01/2012 - 01/2013, 01/2016-12/2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Program in Neurogenetics (J.M.V., T.D., D.H.G., S.P., B.L.F.), Department of Neurology and Department of Human Genetics (D.H.G., B.L.F.), David Geffen School of Medicine, University of California Los Angeles; The Human Genetics Center (L.E.P., J.E.B.), University of Texas School of Public Health, Houston; Fundación Pública Galega de Medicina Xenómica-SERGAS (B.Q., Z.Y., M.J.S.), Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela; Genomic Medicine Group (U711) (B.Q., Z.Y., M.J.S.), Centre for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain; Grupo del Investigación en Genética (Z.Y.), Universidad Simón Bolívar, Barranquilla, Colombia; Department of Molecular and Human Genetics (E.B., D.M., R.G., J.R.L.) and Human Genome Center (J.R.L.), Baylor College of Medicine, Houston, TX; and Department of Integrative Biology and Pharmacology (D.A., R.B.), Institute of Molecular Medicine Center for Metabolic and Degenerative Diseases (R.B.), and Cell and Regulatory Biology Program of The University of Texas Graduate School of Biomedical Sciences (R.B.), McGovern Medical School at The University of Texas Health Science Center at Houston.</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Correspondence to Dr. Fogel: <email>bfogel@ucla.edu</email></corresp>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the article. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000174">Neurology.org/ng</ext-link> for full disclosure forms. The Article Processing Charge was funded by the authors.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>7</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>3</volume>
<issue>4</issue>
<elocation-id>e174</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>9</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2016003707.pdf" xlink:title="pdf"></self-uri>
<abstract>
<sec>
<title>Objective:</title>
<p>To assess the prevalence and clinical features of individuals affected by spinocerebellar ataxia 36 (SCA36) at a large tertiary referral center in the United States.</p>
</sec>
<sec>
<title>Methods:</title>
<p>A total of 577 patients with undiagnosed sporadic or familial cerebellar ataxia comprehensively evaluated at a tertiary referral ataxia center were molecularly evaluated for SCA36. Repeat primed PCR and fragment analysis were used to screen for the presence of a repeat expansion in the <italic>NOP56</italic> gene.</p>
</sec>
<sec>
<title>Results:</title>
<p>Fragment analysis of triplet repeat primed PCR products identified a GGCCTG hexanucleotide repeat expansion in intron 1 of <italic>NOP56</italic> in 4 index cases. These 4 SCA36-positive families comprised 2 distinct ethnic groups: white (European) (2) and Asian (Japanese [1] and Vietnamese [1]). Individuals affected by SCA36 exhibited typical clinical features with gait ataxia and age at onset ranging between 35 and 50 years. Patients also suffered from ataxic or spastic limbs, altered reflexes, abnormal ocular movement, and cognitive impairment.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>In a US population, SCA36 was observed to be a rare disorder, accounting for 0.7% (4/577 index cases) of disease in a large undiagnosed ataxia cohort.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>National Human Genome Research Institute</funding-source>
</award-group>
<award-group>
<funding-source>National Heart Lung and Blood Institute</funding-source>
<award-id>(U54HG006542)</award-id>
</award-group>
<award-group>
<funding-source>National Institute of Neurological Disorders and Stroke (NINDS)</funding-source>
<award-id>R01NS082094</award-id>
</award-group>
<award-group>
<funding-source>National Institutes of Health (NIH)</funding-source>
<award-id>UL1TR000124</award-id>
</award-group>
<award-group>
<funding-source>Spanish Institute of Health</funding-source>
<award-id>(grant PI12/00742)</award-id>
</award-group>
<award-group>
<funding-source>National Institute of Arthritis and Musculoskeletal and Skin Diseases</funding-source>
<award-id>(R01AR059847)</award-id>
</award-group>
<award-group>
<funding-source>National Institute of Diabetes and Digestive and Kidney Diseases</funding-source>
<award-id>(R01DK092590)</award-id>
</award-group>
<award-group>
<funding-source>American Heart Association</funding-source>
<award-id>(15POST25090134)</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body><p>Genetic cerebellar ataxia is a clinically heterogeneous disease that progressively destroys the cerebellum and consequently impairs balance and coordination in the affected individual.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> The diagnosis of cerebellar ataxia can be challenging because there are more than 500 genes associated with either primary or secondary ataxia, and many affected families remain undiagnosed for decades. The introduction of unbiased genomic diagnostic testing methods, such as clinical exome sequencing, into the diagnostic evaluation has greatly improved time to diagnosis,<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref></sup> but is limited in its ability to detect certain forms of genetic mutation such as repeat expansion disorders.<sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref></sup> The spinocerebellar ataxias (SCAs) are a diverse group of neurodegenerative disorders characterized by an autosomal dominant pattern of inheritance and cerebellar symptoms, currently consisting of at least 43 distinct clinical entities, of which 11 are repeat expansion disorders.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> One of these conditions, spinocerebellar ataxia 36 (SCA36), is caused by a GGCCTG hexanucleotide repeat expansion in the first intron of the pre-mRNA processing gene, nucleolar protein 56 (NOP56).<sup><xref ref-type="bibr" rid="R7">7</xref></sup> Individuals with this disorder show progressive, late-onset, ataxic symptoms affecting limb, trunk, and/or gait stability.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> To date, SCA36 prevalence has been reported in regions of Japan,<sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R8">8</xref></sup> Spain,<sup><xref ref-type="bibr" rid="R9">9</xref></sup> France,<sup><xref ref-type="bibr" rid="R8">8</xref></sup> Germany,<sup><xref ref-type="bibr" rid="R8">8</xref></sup> and most recently, in China,<sup><xref ref-type="bibr" rid="R10">10</xref></sup> but its prevalence in the United States is undetermined. Through combined methods of exome sequencing, linkage analysis, and fluorescent repeat primed PCR (RP-PCR), we molecularly identified SCA36 in 4 index cases, representing less than 1% of the undiagnosed population at a tertiary referral ataxia center.</p><sec id="s1" sec-type="methods"><title>METHODS</title><sec id="s1-1"><title>Patient recruitment and diagnostic evaluation.</title><p>All patients were initially seen at our tertiary referral ataxia center for disorders of gait and balance. All patients underwent a comprehensive clinical evaluation for acquired causes of ataxia prior to consideration of genetic causes.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R11">11</xref></sup> For enrollment in this study, patients were required to have negative testing for the most common genetic ataxias worldwide,<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R12">12</xref></sup> specifically SCA1, SCA2, SCA3, SCA6, and SCA7, and Friedreich ataxia if clinically appropriate. Age at onset or mode of inheritance was not used as exclusion criteria to prevent bias against phenotypic variability<sup><xref ref-type="bibr" rid="R3">3</xref></sup> or inaccurate assessment of familial association in relatives who could not be directly assessed clinically.</p></sec><sec id="s1-2"><title>Standard protocol approvals, registrations, and patient consents.</title><p>Written informed consent was obtained to collect DNA for genetic analysis. All patients were provided genetic counseling both before and after completion of the study. All study methods were approved by the Institutional Review Board of the University of California, Los Angeles.</p></sec><sec id="s1-3"><title>Exome sequencing and array genotyping.</title><p>Whole-exome sequencing was performed for 3 members of 2 families (families A and B, <xref ref-type="fig" rid="F1">figure 1A</xref>) at the Human Genome Sequencing Center (HGSC) at Baylor College of Medicine as part of the Baylor-Hopkins Center for Mendelian Genomics initiative. With 0.5 ng of DNA, an Illumina paired-end pre-capture library was generated as described in the BCM-HGSC protocol (<ext-link ext-link-type="uri" xlink:href="https://www.hgsc.bcm.edu/content/protocols-sequencing-library-construction">hgsc.bcm.edu/content/protocols-sequencing-library-construction</ext-link>). Four of these libraries were pooled and then hybridized in solution to the HGSC CORE design<sup><xref ref-type="bibr" rid="R13">13</xref></sup> (52 Mb; NimbleGen, Madison, WI) in accordance with the NimbleGen SeqCap EZ Exome Library SR User's Guide. Each capture pool, containing 4 samples, was sequenced in one lane using the Illumina HiSeq 2000 platform in paired-end mode, with sequencing-by-synthesis reactions extended for 101 cycles from each end and an additional 7 cycles for the index read. On average, each exome yielded 9.6 Gb of data with 93% of the targeted exome bases covered to a depth of 20-fold or greater. Variant calls were generated according to the GATK best practices (Genome Analysis Toolkit 3.4) using the hg19 reference genome and annotated using the SVS Annotation Suite (Golden Helix). Only variants causing nonsynonymous protein-coding changes or splice-site variants were included in the analysis. Annotated variants were filtered according to a minor allele frequency (MAF) using the Exome Aggregation Consortium (ExAC) database<sup><xref ref-type="bibr" rid="R14">14</xref></sup> (r.0.2) (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">exac.broadinstitute.org</ext-link>) at an MAF of 0.1% for genes containing a single heterozygous variant, and 1% for genes containing multiple heterozygous variants or homozygous variants. Variants remaining after filtering were compared to a list of 2,256 genes identified by the keyword “ataxia” in the Online Mendelian Inheritance in Man database<sup><xref ref-type="bibr" rid="R15">15</xref></sup> (<ext-link ext-link-type="uri" xlink:href="http://www.omim.org">omim.org</ext-link>) and assessed for their clinical significance as previously described.<sup><xref ref-type="bibr" rid="R3">3</xref></sup></p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Pedigrees and Southern blot analysis of the SCA36 families identified in this study</title><p>(A) Affected individuals (dark fill) and index cases (arrow) are indicated. +Genotyped individuals; *Individuals who had exome sequencing performed; gray fill indicates at-risk individuals, currently asymptomatic. All genotyped individuals in families A and B were included in the linkage analysis. (B) Southern blot analysis of patient DNA from probands of 3 of the identified SCA36 families, a negative control (−), and a positive control (+). The 3 Kb wild-type allele (arrow) and the larger expanded allele (*) are shown. SCA36 = spinocerebellar ataxia 36.</p></caption><graphic xlink:href="NG2016003707FF1"></graphic></fig><p>In parallel to the exome workflow, Illumina Infinium Human Exome v1-2 array data were generated for linkage analysis from 6 members of family A and 2 members of family B (<xref ref-type="fig" rid="F1">figure 1A</xref>). Array data quality assessment included orthogonal confirmation of sample identity and purity using the Error Rate In Sequencing (ERIS) pipeline developed at the BCM:HGSC. Using an “e-GenoTyping” approach, ERIS screens all sequence reads for exact matches to probe sequences defined by the variant and position of interest. A successfully sequenced sample must meet quality control metrics of ERIS single nucleotide polymorphism (SNP) array concordance (&gt;90%) and ERIS average contamination rate (&lt;5%). These arrays capture more than 240,000 SNPs, which were carried forward into quality filtering, pedigree validation, and linkage analyses. All insertions/deletions and nonautosomal polymorphisms and all variants without an rs identifier were removed. In addition, SNPs were removed for high missingness (&gt;5%) or mapping to identical locations (duplicates) resulting in 227,103 variants for analysis. Pedigrees were validated using the prePRIMUS QC pipeline to estimate pairwise kinship and were reconstructed in PRIMUS.<sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup></p></sec><sec id="s1-4"><title>Linkage analysis.</title><p>To identify overlapping haplotypes shared identically by descent (IBD) by all genotyped cases and not shared by genotyped controls in families A and B (<xref ref-type="fig" rid="F1">figure 1A</xref>), multifamily parametric linkage analysis was conducted using a fully penetrant dominant model with no phenocopies (f<sub>0,1,2</sub> = 0,1,1) using ALLEGRO.<sup><xref ref-type="bibr" rid="R18">18</xref></sup> Logarithm of the odds (LOD) scores generated from linkage in these families are unable to meet genome-wide significance thresholds because of power (max LOD given the information across the pedigrees is 1.2); the purpose of these analyses was to identify candidate regions where IBD sharing was consistent with the model of inheritance for disease in both families for further analysis rather than to identify regions of genome-wide significant linkage. Rare (MAF &lt;0.1% in ExAC), nonsynonymous and splice-site variants from exome sequencing falling within linkage regions (peaks reaching maximum LOD, ∼58.6 megabases genome wide) were identified and evaluated as potential disease candidates (figure e-1 at <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000174">Neurology.org/ng</ext-link>).</p></sec><sec id="s1-5"><title>SCA36 repeat expansion testing.</title><p>DNA was isolated from the peripheral blood and purified using the Gentra Puregene Blood Kit (Qiagen, Hilden, Germany). Fluorescent RP-PCR was implemented,<sup><xref ref-type="bibr" rid="R9">9</xref></sup> and PCR products were separated then analyzed on an ABI Prism 3730 XL Analyzer (Retrogen, San Diego, CA). Peak Scanner 2 software was used to assess for the presence of the SCA36 hexanucleotide repeat expansion in <italic>NOP56</italic>. This method specifically detects expanded alleles and does not assess normal <italic>NOP56</italic> alleles.</p></sec><sec id="s1-6"><title>Southern blot.</title><p>For confirmation of repeat expansions, Southern blot analysis was conducted on DNA samples of 3 affected individuals (<xref ref-type="fig" rid="F1">figure 1B</xref>). Genomic DNA (10 μg) was digested overnight with <italic>BsmI</italic> (New England Biolabs, Ipswich, MA). Digested DNA was resolved on a 0.8% agarose gel, depurinated with 0.25 M HCl, denatured with 1.5 M NaCl, 0.5 M NaOH neutralized with 1.5 M NaCl, 0.5 M Tris-HCl (pH 7.0), and transferred with 20× saline-sodium citrate buffer onto a Hybond-N+ nylon membrane (GE Health care, Piscataway, NJ). DNA was immobilized on the membrane by UV cross-linking. A 464-bp probe for hybridization was synthesized from genomic DNA by PCR using primers<sup><xref ref-type="bibr" rid="R10">10</xref></sup> flanking exons 2 and 3 of <italic>NOP56</italic>. The PCR-amplified probe DNA was used as template to make a 32P-labeled probe using random hexamer primers (#58875; Invitrogen, Carlsbad, CA), Klenow polymerase (#M0210S, NEB) and dNTP's containing [32P]-dCTP. Hybridization with the labeled probe was performed at 65°C overnight. The membrane was developed by X-ray film exposure.</p></sec></sec><sec id="s2" sec-type="results"><title>RESULTS</title><sec id="s2-1"><title>Identification of 2 SCA36 families by exome sequencing and linkage analysis.</title><p>We independently performed exome sequencing on 3 individuals from 2 undiagnosed families (families A and B, <xref ref-type="fig" rid="F1">figure 1A</xref>) with adult-onset dominant cerebellar ataxia given the high diagnostic yield of this testing in patients previously screened for the most common genetic forms of ataxia.<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20">20</xref></sup> However, we were unable to identify any potentially clinically relevant sequence variation associated with ataxia using standard methods.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> To address the possibility of a novel gene or a form of genetic variation not detected by exome sequencing (e.g., noncoding, copy number variants, or repeat expansions), we separately performed genotyping using a cytogenomic SNP array and subsequent linkage analysis in both families. Among these data, we identified 2 regions on chromosome 20 that reached maximum theoretical LOD scores across families A and B containing a known clinical ataxia gene, <italic>NOP56</italic>, causing disease through repeat expansion (figure e-1). Exome analysis had indicated that families A and B did not possess any rare protein-coding variants in any genes potentially associated with their phenotype in any of the identified linked regions (figure e-1). The absence of any clinically relevant rare variants in ataxia genes within the sequenced affected family members (<xref ref-type="fig" rid="F1">figure 1A</xref>) prompted us to evaluate these 2 families for the repeat expansion in <italic>NOP56</italic> associated with SCA36.<sup><xref ref-type="bibr" rid="R7">7</xref></sup></p></sec><sec id="s2-2"><title>Identification of an expanded GGCCTG repeat in <italic>NOP56</italic> in families A and B.</title><p>RP-PCR analysis was used to assess for expansion in the <italic>NOP56</italic> gene. This method specifically detects the presence of an expansion through the generation of multiple products of varying size from different amplification sites, leading to a stuttering effect (figure e-2). RP-PCR identified the pathogenic hexanucleotide repeat expansion in intron 1 of <italic>NOP56</italic> in both families A and B (figure e-2), confirming the diagnosis of SCA36. Because RP-PCR lacks the ability to quantitate expansion size, Southern blot analysis was used as a second confirmatory technique, detecting <italic>NOP56</italic> repeat expansions in the probands from families A and B (<xref ref-type="fig" rid="F1">figure 1B</xref>). Given that SCA36 is considered a rare repeat expansion disorder, but has been observed to have varying prevalence in different ethnic populations,<sup><xref ref-type="bibr" rid="R7">7</xref><xref ref-type="bibr" rid="R8">–</xref><xref ref-type="bibr" rid="R10">10</xref></sup> the finding of 2 consecutive SCA36 families prompted us to evaluate our entire clinical cohort for the disease to determine the prevalence in a US ataxic population. We analyzed 577 index cases using fluorescent RP-PCR. The demographics of this patient population including age, sex, ethnicity, and phenotype are shown in <xref ref-type="table" rid="T1">table 1</xref>. Only 2 additional positive cases were identified, thus bringing the total to 4/577 cases (0.7%).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient demographics</p></caption><graphic xlink:href="NG2016003707TT1"></graphic></table-wrap></sec><sec id="s2-3"><title>Clinical characteristics of SCA36 in US families.</title><p>SCA36 was observed in 4 index cases from a cohort of 577 patients (families A–D; <xref ref-type="fig" rid="F1">figure 1A</xref>). An additional 2 positive cases were subsequently identified (1 each from families A and B, respectively). The ancestral origins of these 4 families were either white, non-Hispanic, European (2 families), or Asian (1 Vietnamese and 1 Japanese family). The clinical features of these 6 individuals (5 men and 1 woman, mean age at onset: 44.5 ± 5.8 years) are summarized in <xref ref-type="table" rid="T2">table 2</xref>. All affected individuals exhibited an ataxia gait, consistent with cerebellar dysfunction, on examination. Other symptoms included limb ataxia or spasticity and altered reflexes. Saccadic ocular pursuit was present in 5 of 6 individuals, predominantly saccadic pursuit or overshoot, whereas hearing impairment was reported in only 1 of 6 individuals. Two of 6 patients presented with mild cerebellar atrophy detected using neuroimaging.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical findings of SCA36 patients reported in this study</p></caption><graphic xlink:href="NG2016003707TT2"></graphic></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>DISCUSSION</title><p>We evaluated 577 index cases seen at a tertiary referral ataxia center in the United States and identified the <italic>NOP56</italic> hexanucleotide repeat expansion in 4 families. When compared with other reports, the prevalence of SCA36 in the United States (n = 577, 0.7%) appears to be less frequent than in most other countries evaluated to date, including Spain (n = 160, 6.3%),<sup><xref ref-type="bibr" rid="R9">9</xref></sup> France (n = 270, 4.4%),<sup><xref ref-type="bibr" rid="R8">8</xref></sup> Western Japan (n = 251, 3.6%),<sup><xref ref-type="bibr" rid="R7">7</xref></sup> and Eastern Japan (n = 231, 2.2%)<sup><xref ref-type="bibr" rid="R8">8</xref></sup> and is more similar to that of China (n = 512, 0.6%)<sup><xref ref-type="bibr" rid="R10">10</xref></sup> and Germany (n = 175, 0.0%)<sup><xref ref-type="bibr" rid="R8">8</xref></sup> (<xref ref-type="table" rid="T3">table 3</xref>). It should be noted that our cohort was of general undiagnosed patients with ataxia, unselected by mode of inheritance or other features, in whom the most frequent genetic etiologies had been previously excluded. As a tertiary referral center, we cannot estimate the number of patients with more common genetic etiologies identified in the community, and therefore not referred, so the overall prevalence in all undiagnosed ataxia cases is likely lower. Consistent with previous reports, SCA36-positive individuals in our cohort descended from European and East Asian backgrounds. Despite the majority of our cohort descending from European or Asian ancestry (<xref ref-type="table" rid="T1">table 1</xref>), we observe a much lower prevalence than countries such as Spain, France, or Japan.<sup><xref ref-type="bibr" rid="R7">7</xref><xref ref-type="bibr" rid="R8">–</xref><xref ref-type="bibr" rid="R9">9</xref></sup> This may stem partially from the inclusion criteria defining our cohort, but likely also reflects regional variation across Europe and Asia, as noted in the studies from China and Germany,<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R10">10</xref></sup> for example. One of our families (family B) identifies their family origins as emanating from Vietnam, which would be the first reported case of SCA36 from that country.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison of clinical characteristics of US SCA36 patients with other SCA36 populations globally</p></caption><graphic xlink:href="NG2016003707TT3"></graphic></table-wrap><p>Clinical examination of those 6 affected SCA36 patients in our cohort confirms many of the previously reported SCA36 symptoms, including gait and limb ataxia, dysarthria, increased lower limb reflexes, polyneuropathy, saccadic pursuit, and cognitive impairment (<xref ref-type="table" rid="T3">table 3</xref>). Facial or tongue fasciculations are typically seen in more than 50% of reported SCA36-positive cases with the exception of France (12%) and were present in 2 of 6 (33%) SCA36-positive individuals in this study. Hearing impairment is present in more than 40% of previously reported SCA36-positive individuals and was also reported in 2 of 6 individuals from family B (<xref ref-type="fig" rid="F1">figure 1A</xref> and <xref ref-type="table" rid="T2">table 2</xref>), although detailed audiologic studies were not conducted on all the affected patients in this study. In summary, SCA36 represents a small percentage of the undiagnosed cerebellar ataxia population in the United States. Given that SCA36 is a repeat expansion disorder that would not be detected by the high-yield genomic diagnostic tests performed early in a patient's evaluation,<sup><xref ref-type="bibr" rid="R3">3</xref></sup> repeat expansion testing should be considered in individuals with appropriate clinical phenotypes and either a sporadic or dominant mode of inheritance.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="PMC_1">
<caption>
<title>Data Supplement</title>
</caption>
<media mime-subtype="html" mimetype="text" xlink:href="supp_3_4_e174__index.html"></media>
<media mime-subtype="msword" mimetype="application" xlink:href="supp_3.4.e174_Supplemental_Data.docx" xlink:role="associated-file"></media>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>Supplemental data at <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000174">Neurology.org/ng</ext-link></p>
</fn>
</fn-group>
<ack>
<title>ACKNOWLEDGMENT</title>
<p>The authors thank all the patients and their families who contributed to this study. B.L.F.thanks Xizhe Wang and Stephanie Pang for technical assistance.</p>
</ack>
<sec sec-type="contributions">
<title>AUTHOR CONTRIBUTIONS</title>
<p content-type="contributions">B.L.F., J.E.B., M.J.S., and J.R.L. contributed to the conception and design of the research project, and J.M.V., T.D., and L.E.P. were responsible for its execution. S.P., B.L.F., and D.H.G. supervised the clinical data, samples, and patient care. B.Q. and Z.Y. contributed to the RP-PCR protocol design and control sample preparation. E.B., D.M., R.G., J.R.L., and B.L.F. contributed to next-generation sequencing design and analysis. L.E.P. and J.E.B. conducted all bioinformatics analyses. D.A. and R.B. performed the Southern blot analysis as shown in figure 1B. J.M.V., T.D., and B.L.F. wrote the manuscript, and all authors were responsible for its review and critique.</p>
</sec>
<sec sec-type="funding">
<title>STUDY FUNDING</title>
<p content-type="funding">This work was supported in part by a US National Human Genome Research Institute and National Heart Lung and Blood Institute grant (U54HG006542) to the Baylor-Hopkins Center for Mendelian Genomics, the National Institute for Neurologic Disorders and Stroke (grant R01NS082094 to Dr. Fogel), and the National Ataxia Foundation (Young Investigator Award to Dr. Fogel). The research described was supported by the NIH/National Center for Advancing Translational Science UCLA Clinical and Translational Science Institute grant UL1TR000124. Dr. Fogel acknowledges the support through donations to the University of California by the Rochester Ataxia Foundation. The authors also received support from the Spanish Institute of Health Carlos III (grant PI12/00742) and FEDER funds. Z.Y. was supported by a grant from Fundación Carolina. R.B. was supported by grants from the NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR059847), and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK092590). D.A. was supported by the American Heart Association (15POST25090134).</p>
</sec>
<sec sec-type="disclosure">
<title>DISCLOSURE</title>
<p content-type="disclosure">J.M. Valera, T. Diaz, and L.E. Petty report no disclosures. B. Quintáns has been a consultant for Genomic Consulting S.L. Z. Yáñez reports no disclosures. E. Boerwinkle has received research support from NIH. D. Muzny has received research support from NIH and the Simons Foundation. D. Akhmedov has received research support from the American Heart Association. R. Berdeaux has received research support from NIH. M.J. Sobrido has received speaker honoraria from Actelion Pharmaceuticals; has served on the editorial boards of <italic>Human Mutation</italic> and <italic>Applied &amp; Translational Genomics</italic>; is the CEO of Genomic Consulting; has a private clinical neurology practice and performs genetic diagnosis of ataxias; and has received research support from Actelion Pharmaceuticals, Instituto de Salud Carlos III (Spain), and the Asociación Galega de Ataxias (AGA). R. Gibbs has received travel funding/speaker honoraria from Fusion Conference; has served on the editorial board of <italic>Genome Research</italic>; and has received research support from NIH. J.R. Lupski has stock ownership in 23andMe; is a paid consultant for Regeneron Pharmaceuticals; has stock options in Lasergen; is a member of the scientific advisory boards of Baylor Genetics Laboratories, Lasergen Inc., Regeneron Pharmaceuticals, and BioPontis Alliance for Rare Diseases; receives publishing royalties from <italic>Humana Press</italic>; is an employee of Baylor College of Medicine (the Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis and clinical exome sequencing offered in the Baylor Genetics Laboratory [<ext-link ext-link-type="uri" xlink:href="http://www.bmgl.com/">bmgl.com</ext-link>]); has received research support from NIH; and is a coinventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. D.H. Geschwind has served on the scientific advisory board for Ovid Therapeutics; has served on the editorial boards of <italic>Cell</italic>, <italic>Molecular Autism</italic>, <italic>Molecular Neuropsychiatry</italic>, <italic>Nature</italic>, <italic>Nature Genetics</italic>, <italic>Nature Neuroscience</italic>, <italic>Neurology</italic>, <italic>Neuron</italic>, <italic>New England Journal of Medicine</italic>, <italic>Public Library of Science (PLoS)</italic>, <italic>Genetics</italic>, <italic>Science</italic>, and <italic>Translational Psychiatry</italic>; holds patents for Peripheral Gene Expression Biomarkers for Autism, Genetic Risk Factor for Neurodegenerative Disease, Compositions and Methods for Diagnosing and Treating Brain Cancer and Identifying Neural Stem Cells, Genetic Variants Underlying Human Cognition: Novel Diagnostic and Therapeutic Targets, Peripheral Gene Expression Biomarkers for Autism, Brain Gene Expression Changes Associated with Autism Spectrum Disorders, Full Biomarkers in Friedreich's Ataxia (provisional patent application), Signaling Networks Causing Neurodevelopmental Disorders In Human Neurons, Genes Dysregulated in Autism: Potential Biomarkers and Therapeutic Pathways, Peripheral Gene Expression Biomarkers for Autism, A Genetic Target for Treatment of Individuals with Neurocognitive Spectrum Disorders, Neuronal Regeneration, Frataxin Knock-Down Mouse, Jakmip1 Knockout Mouse, and Cyfip1 Transgenic Mouse; receives publishing royalties from Oxford University Press; has been a consultant for Ovid Therapeutics Ltd; has received research support from Takeda Pharmaceutical Company, NIH, the Simons Foundation, Adelson Medical Research Foundation, The Tau Consortium, and Ovid Therapeutics Ltd; and receives license fee payments for Mouse model of Friedreich Ataxia. S. Perlman has received research support from the University of California, Los Angeles and the National Ataxia Foundation. J.E. Below has received research support from Sanofi Innovation Awards Program, Tulane National Primate Research Center, and NIH. B.L. Fogel has received speaker honoraria from the American Academy of Neurology; has received travel funding from the National Ataxia Foundation; has received speaker honoraria and travel funding from American Physician Institute for Advanced Professional Studies; and has received research support from NIH and the National Ataxia Foundation. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000174">Neurology.org/ng</ext-link> for full disclosure forms.</p>
</sec>
<glossary>
<title>GLOSSARY</title>
<def-list>
<def-item>
<term id="G1">ERIS</term>
<def>
<p>Error Rate In Sequencing (ERIS)</p>
</def>
</def-item>
<def-item>
<term id="G2">IBD</term>
<def>
<p>identically by descent</p>
</def>
</def-item>
<def-item>
<term id="G3">LOD</term>
<def>
<p>logarithm of the odds</p>
</def>
</def-item>
<def-item>
<term id="G4">MAF</term>
<def>
<p>minor allele frequency</p>
</def>
</def-item>
<def-item>
<term id="G5">RP-PCR</term>
<def>
<p>repeat primed PCR</p>
</def>
</def-item>
<def-item>
<term id="G6">SCA</term>
<def>
<p>spinocerebellar ataxia</p>
</def>
</def-item>
<def-item>
<term id="G7">SCA36</term>
<def>
<p>spinocerebellar ataxia 36</p>
</def>
</def-item>
<def-item>
<term id="G8">SNP</term>
<def>
<p>single nucleotide polymorphism</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shakkottai</surname><given-names>VG</given-names></name>, <name name-style="western"><surname>Fogel</surname><given-names>BL</given-names></name></person-group>
<article-title>Autosomal dominant spinocerebellar ataxia</article-title>. <source/>Neurol Clin
<year>2013</year>;<volume>31</volume>:<fpage>987</fpage>–<lpage>1007</lpage>.<pub-id pub-id-type="pmid">24176420</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pyle</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Smertenko</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bargiela</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Exome sequencing in undiagnosed inherited and sporadic ataxias</article-title>. <source/>Brain
<year>2015</year>;<volume>138</volume>:<fpage>276</fpage>–<lpage>283</lpage>.<pub-id pub-id-type="pmid">25497598</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogel</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Deignan</surname><given-names>JL</given-names></name>, <etal>et al</etal></person-group>
<article-title>Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia</article-title>. <source/>JAMA Neurol
<year>2014</year>;<volume>71</volume>:<fpage>1237</fpage>–<lpage>1246</lpage>.<pub-id pub-id-type="pmid">25133958</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogel</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Strom</surname><given-names>SP</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clinical exome sequencing in neurogenetic and neuropsychiatric disorders</article-title>. <source/>Ann NY Acad Sci
<year>2016</year>;<volume>1366</volume>:<fpage>49</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">26250888</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogel</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Satya-Murti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>BH</given-names></name></person-group>
<article-title>Clinical exome sequencing in neurologic disease</article-title>. <source/>Neurol Clin Pract
<year>2016</year>;<volume>6</volume>:<fpage>164</fpage>–<lpage>176</lpage>.<pub-id pub-id-type="pmid">27104068</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durr</surname><given-names>A</given-names></name></person-group>
<article-title>Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond</article-title>. <source/>Lancet Neurol
<year>2010</year>;<volume>9</volume>:<fpage>885</fpage>–<lpage>894</lpage>.<pub-id pub-id-type="pmid">20723845</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Abe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Matsuura</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement</article-title>. <source/>Am J Hum Genet
<year>2011</year>;<volume>89</volume>:<fpage>121</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">21683323</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obayashi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stevanin</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Synofzik</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Spinocerebellar ataxia type 36 exists in diverse populations and can be caused by a short hexanucleotide GGCCTG repeat expansion</article-title>. <source/>J Neurol Neurosurg Psychiatry
<year>2015</year>;<volume>86</volume>:<fpage>986</fpage>–<lpage>995</lpage>.<pub-id pub-id-type="pmid">25476002</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>García-Murias</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Quintáns</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Arias</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>“Costa da Morte” ataxia is spinocerebellar ataxia 36: clinical and genetic characterization</article-title>. <source/>Brain
<year>2012</year>;<volume>135</volume>:<fpage>1423</fpage>–<lpage>1435</lpage>.<pub-id pub-id-type="pmid">22492559</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>YC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Spinocerebellar ataxia type 36 in the Han Chinese</article-title>. <source/>Neurol Genet
<year>2016</year>;<volume>2</volume>:<fpage>e68</fpage>
<ext-link ext-link-type="uri" xlink:href="http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000068">doi: 10.1212/NXG.0000000000000068</ext-link>.<pub-id pub-id-type="pmid">27123487</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fogel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group>
<article-title>Cerebellar disorders: balancing the approach to cerebellar ataxia</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Tuite</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Gálvez-Jiménez</surname><given-names>N</given-names></name></person-group>, editors. <source/>Uncommon Causes of Movement Disorders. <publisher-loc>New York</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>; <year>2011</year>:<fpage>198</fpage>–<lpage>216</lpage>.</mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogel</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Lane</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Mutations in rare ataxia genes are uncommon causes of sporadic cerebellar ataxia</article-title>. <source/>Mov Disord
<year>2012</year>;<volume>27</volume>:<fpage>442</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">22287014</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bainbridge</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yuanqing</surname><given-names>W</given-names></name>, <etal>et al</etal></person-group>
<article-title>Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities</article-title>. <source/>Genome Biol
<year>2011</year>;<volume>12</volume>:<fpage>R68</fpage>.<pub-id pub-id-type="pmid">21787409</pub-id></mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="book"><collab>Exome Aggregation Consortium (ExAC)</collab>. <source/>ExAC Browser. <publisher-loc>Cambridge, MA</publisher-loc>: <year>2014</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://biorxiv.org/content/early/2015/10/30/030338">http://biorxiv.org/content/early/2015/10/30/030338</ext-link>. Accessed December 2015.</mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="book"><collab>McKusick-nathans Institute of Genetic Medicine; Johns Hopkins Medicine; National Human Genome Research Institute</collab>. <source/>Online Mendelian Inheritance in Man. Avaiable at: <ext-link ext-link-type="uri" xlink:href="http://omim.org/">http://omim.org/</ext-link>. Accessed December 2015.</mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staples</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Qiao</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>MH</given-names></name>, <etal>et al</etal></person-group>
<article-title>PRIMUS: rapid reconstruction of pedigrees from genome-wide estimates of identity by descent</article-title>. <source/>Am J Hum Genet
<year>2014</year>;<volume>95</volume>:<fpage>553</fpage>–<lpage>564</lpage>.<pub-id pub-id-type="pmid">25439724</pub-id></mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staples</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ekunwe</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lange</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>PRIMUS: improving pedigree reconstruction using mitochondrial and Y haplotypes</article-title>. <source/>Bioinformatics
<year>2016</year>;<volume>32</volume>:<fpage>596</fpage>–<lpage>598</lpage>.<pub-id pub-id-type="pmid">26515822</pub-id></mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gudbjartsson</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Jonasson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Frigge</surname><given-names>ML</given-names></name>, <etal>et al</etal></person-group>
<article-title>Allegro, a new computer program for multipoint linkage analysis</article-title>. <source/>Nat Genet
<year>2000</year>;<volume>25</volume>:<fpage>12</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">10802644</pub-id></mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohba</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Osaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Iai</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Diagnostic utility of whole exome sequencing in patients showing cerebellar and/or vermis atrophy in childhood</article-title>. <source/>Neurogenetics
<year>2013</year>;<volume>14</volume>:<fpage>225</fpage>–<lpage>232</lpage>.<pub-id pub-id-type="pmid">24091540</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawyer</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Schwartzentruber</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Beaulieu</surname><given-names>CL</given-names></name>, <etal>et al</etal></person-group>; <collab>FORGE Canada Consortium</collab>. <article-title>Exome sequencing as a diagnostic tool for pediatric-onset ataxia</article-title>. <source/>Hum Mutat
<year>2014</year>;<volume>35</volume>:<fpage>45</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">24108619</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>